Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial.

ABSTRACT:

Background

Aspirin use is an effective strategy for the chemoprevention of colorectal cancer, even at low doses. However, in order to implement aspirin interventions, risk-benefit balances and biologic mechanisms need to be better defined; to further this aim, we used a metabolomics approach.

Methods

We metabolically profiled 40 healthy, nonsmoking men and women ages 20 to 45 years enrolled in a randomized, double-blind, crossover trial of 325 mg aspirin/day over a period of 60 days. Gas and liquid chromatography-mass spectrometry were used to comprehensively profile participants' plasma samples after aspirin and placebo interventions.

Results

A total of 363 metabolites, covering most human biochemical pathways, were measured. Compared with placebo-treated participant

SUBMITTER: Liesenfeld DB 

PROVIDER: S-EPMC4911817 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature